1-(Chloromethyl)-3-(cyclopropylmethyl)benzene | 921602-55-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(Chloromethyl)-3-(cyclopropylmethyl)benzene
• CAS: 921602-55-3
• 化学式: C₁₁H₁₃Cl
• 分子量: 180.67
• InChiKey: KKIVLFVAXZOGJI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为产物：
  描述：

  [3-(Cyclopropylmethyl)phenyl]methanol 、 、 三苯基膦 、 四氯化碳 反应 16.0h， 生成 1-(Chloromethyl)-3-(cyclopropylmethyl)benzene
  参考文献：
  名称：

  Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease

  摘要：

  本发明涉及式（I）及其互变异构体的螺环吡啶化合物，这些化合物是β-分泌酶酶的抑制剂，并且在治疗β-分泌酶酶参与的疾病，如阿尔茨海默病方面是有用的。本发明还涉及包括这些化合物的制药组合物以及在治疗β-分泌酶酶参与的这些疾病中使用这些化合物和组合物的用途。

  公开号：

  US20070021454A1

文献信息

• Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease
  申请人：Coburn A. Craig

  公开号：US20070021454A1

  公开（公告）日：2007-01-25

  The present invention is directed to spiropiperidine compounds of formula (I) and tautomers thereof, which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及式（I）及其互变异构体的螺环吡啶化合物，这些化合物是β-分泌酶酶的抑制剂，并且在治疗β-分泌酶酶参与的疾病，如阿尔茨海默病方面是有用的。本发明还涉及包括这些化合物的制药组合物以及在治疗β-分泌酶酶参与的这些疾病中使用这些化合物和组合物的用途。
• SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
  申请人：Merck & Co., Inc.

  公开号：EP1910364A2

  公开（公告）日：2008-04-16
• US8211904B2
  申请人：——

  公开号：US8211904B2

  公开（公告）日：2012-07-03
• [EN] SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE<br/>[FR] INHIBITEURS DE SPIROPIPERIDINE BETA-SECRETASE POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
  申请人：MERCK & CO INC

  公开号：WO2007011833A2

  公开（公告）日：2007-01-25

  [EN] The present invention is directed to spiropiperidine compounds of formula (I) and tautomers thereof, which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
  [FR] Cette invention concerne des composés de spiropipéridine représentés par la formule (I) et des tautomères de ces composés, qui constituent des inhibiteurs de l'enzyme bêta-sécrétase et qui sont utiles dans le traitement des maladies dans lesquelles l'enzyme bêta-sécrétase est impliquée, telles que la maladie d'Alzheimer. Cette invention concerne également des compositions pharmaceutiques comprenant ces composés et l'utilisation de ces composés et de ces compositions dans le traitement des maladies dans lesquelles l'enzyme bêta-sécrétase est impliquée.
• Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
  申请人：Merck, Sharp & Dohme Corp.

  公开号：US08211904B2

  公开（公告）日：2012-07-03

  The present invention is directed to spiropiperidine compounds of formula (I) and tautomers thereof, which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及公式(I)的螺环吡啶化合物及其互变异构体，其为β-分泌酶酶抑制剂，可用于治疗涉及β-分泌酶酶的疾病，如阿尔茨海默病。本发明还涉及包含这些化合物的制药组合物以及将这些化合物和组合物用于治疗涉及β-分泌酶酶的疾病的用途。